

(10) International Publication Number
WO 2016/043997 A1(43) International Publication Date
24 March 2016 (24.03.2016)

(51) International Patent Classification:

A61K 31/542 (2006.01) C07K 16/18 (2006.01)
C07D 513/04 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2015/048807

(22) International Filing Date:

8 September 2015 (08.09.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/050,967 16 September 2014 (16.09.2014) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US];
Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **MAY, Patrick Cornelious**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **MERGOTT, Dustin James**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agents: **LENTZ, Nelsen L.** et al.; Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR



(57) Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an anti-N3pGlu Abeta monoclonal antibody.